Get the Stockscreener App
412.25
1.41%
-5.5866
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $412.25, with a volume of 389.50K.
It is down -1.41% in the last 24 hours and up +15.97% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$417.84
Open:
$413.76
24h Volume:
389.50K
Relative Volume:
0.15
Market Cap:
$222.92B
Revenue:
$37.30B
Net Income/Loss:
$7.80B
P/E Ratio:
28.67
EPS:
14.3793
Net Cash Flow:
$8.60B
1W Performance:
+0.25%
1M Performance:
+15.97%
6M Performance:
+11.59%
1Y Performance:
+41.92%
1-Day Range:
$410.50
$416.03
1-Week Range:
$406.42
$421.79
52-Week Range:
$269.77
$421.79
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
412.06 | 225.15B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,184.83 | 1.09T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
260.46 | 628.65B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
249.77 | 439.59B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
134.26 | 327.94B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
150.99 | 289.52B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Hold |
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
AMGN Maintained by Barclays -- Price Target Raised to $380 - GuruFocus
Amgen stock holds near 52-week high after earnings beat and insider sale - AD HOC NEWS
Amgen (AMGN) Stock Looks Below Fair Value As Caution Lingers - simplywall.st
Amgen stock holds above $417 as Q2 2026 beats drive higher guidance - AD HOC NEWS
Insider Selling: Amgen (NASDAQ:AMGN) SVP Sells $521,370.36 in Stock - marketbeat.com
Insider Selling: Amgen (NASDAQ:AMGN) SVP Sells $825,140.00 in Stock - marketbeat.com
Amgen SVP Rachna Khosla sells $1.35m of stock By Investing.com - Investing.com India
Amgen SVP Rachna Khosla sells $1.35m of stock - Investing.com
Amgen stock holds above $415 as strong Q2 2026 results lift guidance - AD HOC NEWS
Daiwa Securities Adjusts Price Target on Amgen to $430 From $390, Keeps Outperform Rating - marketscreener.com
Barclays Adjusts Price Target on Amgen to $380 From $360, Maintains Equalweight Rating - marketscreener.com
Amgen stock holds near a yearly high after Q2 beats - AD HOC NEWS
Amgen’s Q2 Earnings Call: Our Top 5 Analyst Questions - finance.yahoo.com
Is Amgen (AMGN) Fully Valued On Strong Q2 Results And Raised 2026 Guidance? - simplywall.st
CEO Bob Bradway’s Advice to the Next Generation of Innovators - Amgen
Does Amgen (NASDAQ:AMGN) Fit Into The Biotech and Biosimilar Story? - Kalkine Media
Amgen Stock And The Price Of A Promise - Trefis
Amgen Lifts Outlook on Strong Drug Sales, to End Early Development of Obesity Treatment - WSJ
Amgen stock trades near a yearly high after Q2 beats - AD HOC NEWS
Tema ETFs LLC Increases Stock Position in Amgen Inc. $AMGN - marketbeat.com
G&S Capital LLC Makes New $1.58 Million Investment in Amgen Inc. $AMGN - marketbeat.com
AMGEN TO OPEN NEW SCIENCE & INNOVATION CENTER IN GENOME VALLEY, HYDERABAD - PR Newswire
Amgen (AMGN) Q2 2026 Earnings Call Transcript - AOL.com
$1000 Invested In Amgen 15 Years Ago Would Be Worth This Much Today - benzinga.com
Amgen (NASDAQ:AMGN) Hits New 1-Year HighHere's Why - marketbeat.com
Handelsbanken Fonder AB Has $125.51 Million Stake in Amgen Inc. $AMGN - marketbeat.com
Amgen Inc. $AMGN Shares Acquired by KMG Fiduciary Partners LLC - marketbeat.com
Charles Schwab Trust Co Increases Stock Position in Amgen Inc. $AMGN - marketbeat.com
Amgen (AMGN) director Charles Holley receives stock award and reports trust holdings - stocktitan.net
Amgen (AMGN) director Michael V. Drake granted 63.8764 shares in equity award - stocktitan.net
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
Guggenheim raises Amgen stock price target to $388 on strong quarter - Investing.com Canada
Amgen Inc. (AMGN) Stock Analysis: Navigating a Strong Market Cap with High Return on Equity - DirectorsTalk Interviews
AMGEN INC : HSBC RAISES TARGET PRICE TO $445 FROM $425 - Bitget
AMGEN INC : GUGGENHEIM RAISES TARGET PRICE TO $388 FROM $343 - Bitget
Erste Group Bank Brokers Lower Earnings Estimates for Amgen - marketbeat.com
Amgen Stock Jumped 8% This Week After a Guidance Raise. Here’s What’s Next - TIKR.com
Amgen Inc. (AMGN) Stock forecasts - Yahoo Finance UK
Avity Investment Management Inc. Has $27.59 Million Stock Holdings in Amgen Inc. $AMGN - marketbeat.com
Cardano Risk Management B.V. Sells 14,358 Shares of Amgen Inc. $AMGN - marketbeat.com
Amgen Inc. Just Recorded A 17% EPS Beat: Here's What Analysts Are Forecasting Next - 富途牛牛
MRA Advisory Group Grows Holdings in Amgen Inc. $AMGN - marketbeat.com
Teamwork Financial Advisors LLC Sells 8,835 Shares of Amgen Inc. $AMGN - marketbeat.com
Amgen Inc (AMG) Q2 2026 Earnings ReportResults, Call & Slides - TipRanks
Assenagon Asset Management S.A. Has $69.25 Million Position in Amgen Inc. $AMGN - marketbeat.com
Abner Herrman & Brock LLC Decreases Stock Holdings in Amgen Inc. $AMGN - marketbeat.com
Amgen (NASDAQ:AMGN) Upgraded by Wall Street Zen to "Buy" Rating - MarketBeat
Amgen SVP & CCO Nancy Grygiel disposes of $1.19m in stock - Investing.com
Amgen Inc. Stock 12‑Month Price Target Raised to $378.67, Implies 6% Downside - TradingView
Insider Selling: Amgen (NASDAQ:AMGN) SVP Sells 2,970 Shares of Stock - MarketBeat
Amgen: The Market Is Underestimating Its Next Growth Phase (NASDAQ:AMGN) - Seeking Alpha
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amgen Inc Stock (AMGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Khosla Rachna | SVP, Business Development |
Aug 11 '26 |
Sale |
412.57 |
2,000 |
825,134 |
6,404 |
| Khosla Rachna | SVP, Business Development |
Aug 13 '26 |
Sale |
416.43 |
1,252 |
521,365 |
6,404 |
0.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):